NCT00185874TerminatedPhase 1
A Phase I Trial of Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Stanford University
- Enrollment
- 22
- Locations
- 2
- Primary Endpoint
- To determine the feasibility of harvesting autologous dendritic cells (DC) for CT-guided intratumoral DC injection
Study Overview
Brief Summary
Up to twenty-two patients will be enrolled in this study to receive autologous dendritic cells (DCs) administered intratumorally into liver metastases following radiofrequency thermal ablation of those lesions. Patients will receive two vaccinations of DCs at monthly intervals. A dose escalation study of DCs will be included in this study in an attempt to define the maximum tolerated dose of administered DCs.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must have a histologically confirmed colorectal or neuroendocrine cancer with two or more hepatic metastatic lesions.
- •Patients must have unresectable liver metastasis by virtue of:
- •Bi-lobar disease.
- •Extra-hepatic disease.
- •Patients for whom there are medical contraindications to surgery.
- •Anatomic sites within the liver that in the opinion of our surgeon would likely be left with positive margin.
- •Patient must have a minimum of 2 RFA-eligible lesion in the liver. Such as hepatic lesions that are 5 cm or smaller and that are accessible to RF ablation, which in general excludes sites contiguous with critical structures such as bowel or central bile duct and also those that are not amenable to radiographic localization such as small lesions in the dome of the liver. Extra-hepatic disease will be allowed provided that the liver lesions represent the most life-threatening site for that patient. Examples include sub centimeter asymptomatic lung metastases or asymptomatic retroperitoneal lymph nodes or peritoneal metastases
- •Evaluable disease by CT scan or MRI in addition to the lesions to be treated with RFA.
- •More than 4 weeks must have elapsed from the time of major surgery or completion of the last dose of chemotherapy, radiation therapy, investigational therapy and patients must adequately recover from these effects.
- •Life expectancy of >3 months.
- •Karnofsky performance status >70%.
- •Patients must have normal organ and marrow functions as defined below:
- •absolute neutrophil count >1,500/mm^3
- •platelets >70,000/mm^3
- •total bilirubin <1.5 mg/dL
- •AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
- •creatinine within normal institutional limits OR
- •creatinine clearance >60mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.
- •albumin > 2.8 mg/dL
- •Patients must have adequate clotting function (platelet > 70k; INR<1.4; PTT<60).
- •Age >18 years.
- •The effects of DCs on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •No history of autoimmune diseases.
- •Ability to understand the willingness to sign a written informed consent document.
Exclusion Criteria
- •Patients may not be receiving anticoagulation therapy.
- •Patients may not be receiving any other investigational agents.
- •Patients with known brain metastases will be excluded because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurological and other adverse effects.
- •Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
- •Patients with a history of portal hypertension, cirrhosis/hepatitis, or with radiographic evidence of cirrhosis and/or varices are at high risk for developing a complication when undergoing a liver biopsy and may be excluded at the investigators' discretion from participation in this protocol.
- •Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV.
Outcomes
Primary Outcomes
To determine the feasibility of harvesting autologous dendritic cells (DC) for CT-guided intratumoral DC injection
Time Frame: NA- study terminated
To establish the maximally tolerated dose (MTD) and dose limiting toxicity (DLT) of intratumoral autologous dendritic cell vaccination in combination with radiofrequency ablation (RFA) of liver metastases.
Time Frame: NA- study terminated
To determine the toxicity of this regimen
Time Frame: NA- study terminated
Secondary Outcomes
- To determine the activity of this regimen as determined by tumor marker response, pathologic response and radiographic response of treated lesions.(NA- study terminated)
- To evaluate the immune response of patients treated with RFA + DC based on the presence and characterization of tumor infiltrating white blood cells(NA- study terminated)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 1
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerStage III Hepatocellular Carcinoma AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Hepatocellular CarcinomaUnresectable Intrahepatic CholangiocarcinomaNCT03942328Mayo Clinic85
Withdrawn
Phase 1
Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.LymphomaNCT00637117Baylor Research Institute
Withdrawn
Phase 2
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast CancerAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaUnresectable Triple-Negative Breast CarcinomaNCT05539365Roswell Park Cancer Institute19
Completed
Phase 1
Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain TumorsBrain TumorsNCT00893945Rockefeller University19
Unknown
Phase 2
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed GlioblastomaNewly Diagnosed GlioblastomaNCT03400917Aivita Biomedical, Inc.55